M
Matthew G. Ewend
Researcher at University of North Carolina at Chapel Hill
Publications - 129
Citations - 7936
Matthew G. Ewend is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 40, co-authored 125 publications receiving 7111 citations. Previous affiliations of Matthew G. Ewend include Johns Hopkins University School of Medicine & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
The molecular portraits of breast tumors are conserved across microarray platforms
Zhiyuan Hu,Cheng Fan,Daniel S. Oh,James Stephen Marron,Xiaping He,Bahjat F. Qaqish,Chad A. Livasy,Lisa A. Carey,Evangeline R Reynolds,Lynn G. Dressler,Andrew B. Nobel,Joel S. Parker,Matthew G. Ewend,Lynda R. Sawyer,Junyuan Wu,Yudong Liu,Rita Nanda,Maria Tretiakova,Alejandra Ruiz Orrico,Donna Dreher,Juan P. Palazzo,Laurent Perreard,Edward W. Nelson,Mary C. Mone,Heidi Theil Hansen,Michael Mullins,John Quackenbush,Matthew J. Ellis,Olufunmilayo I. Olopade,Philip S. Bernard,Charles M. Perou +30 more
TL;DR: This study validates the "breast tumor intrinsic" subtype classification as an objective means of tumor classification that should be translated into a clinical assay for further retrospective and prospective validation.
Journal ArticleDOI
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
Nan Lin,Lisa A. Carey,Minetta C. Liu,Jerry Younger,Steven E. Come,Matthew G. Ewend,Gordon J. Harris,Elizabeth Bullitt,Annick D. Van den Abbeele,John W. Henson,Xiaochun Li,Rebecca Gelman,Harold J. Burstein,Elizabeth Kasparian,David G. Kirsch,Ann Crawford,Fred H. Hochberg,Eric P. Winer +17 more
TL;DR: The study did not meet the predefined criteria for antitumor activity in highly refractory patients with HER-2-positive brain metastases, and further studies are underway utilizing volumetric changes as a primary end point.
Journal ArticleDOI
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M. Liau,Keyoumars Ashkan,David Tran,Jian Campian,John E. Trusheim,Charles S. Cobbs,Jason Heth,Michael Salacz,Sarah A. Taylor,Stacy D. D’Andre,Fabio M. Iwamoto,Edward J. Dropcho,Yaron A. Moshel,Kevin A. Walter,Clement Pillainayagam,Robert Aiken,Rekha Chaudhary,Samuel Goldlust,Daniela A. Bota,Paul Duic,Jai Grewal,Heinrich Elinzano,Steven A. Toms,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Steven Brem,Matthew G. Ewend,Simon Khagi,Jana Portnow,Lyndon Kim,William G. Loudon,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Scott Lindhorst,Jose Lutzky,Andrew E. Sloan,Gabriele Schackert,Dietmar Krex,Hans-Jorg Meisel,Julian Wu,Raphael P. Davis,Christopher Duma,Arnold B. Etame,David Mathieu,Santosh Kesari,David Piccioni,Manfred Westphal,David S. Baskin,Pamela Z. New,Michel Lacroix,Sven-Axel May,Timothy J. Pluard,Victor Tse,Richard M. Green,John L. Villano,Michael Pearlman,Kevin Petrecca,Michael Schulder,Lynne Taylor,Anthony E. Maida,Robert M. Prins,Timothy F. Cloughesy,Paul Mulholland,Marnix L. Bosch +68 more
TL;DR: Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival, and overall adverse events withDCVax were comparable to standard Therapy alone.
Journal ArticleDOI
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.
Britta Weigelt,Zhiyuan Hu,Xiaping He,Chad A. Livasy,Lisa A. Carey,Matthew G. Ewend,Annuska M. Glas,Charles M. Perou,Laura J. van't Veer +8 more
TL;DR: The results suggest that the capacity to metastasize is an inherent feature of most breast cancers and imply that poor prognosis breast carcinomas classified either by the intrinsic gene set or the 70 prognosis genes represent distinct disease entities that seem sustained throughout the metastatic process.
Journal Article
Pharmacokinetics of Interstitial Delivery of Carmustine, 4-Hydroperoxycyclophosphamide, and Paclitaxel from a Biodegradable Polymer Implant in the Monkey Brain
Lawrence K. Fung,Matthew G. Ewend,Allen K. Sills,Eric P. Sipos,Reid C. Thompson,Mark Watts,O. Michael Colvin,Henry Brem,W. Mark Saltzman +8 more
TL;DR: Pharmacokinetic analysis indicated that tissue exposure to carmustine area under concentration-time curve achieved by polymeric delivery was 4-1200 times higher than that produced by i.v. administration of a higher dose.